Semax
Research Use Only | Not for Human Consumption
A synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH(4-10) fragment; supplied in lyophilized form.
Semax is a synthetic heptapeptide derived from adrenocorticotropic hormone fragment ACTH(4-10) with a C-terminal Pro-Gly-Pro extension. Published preclinical investigations have examined its interactions with BDNF and NGF gene expression, melanocortin receptor binding, and monoaminergic signaling in rodent and in vitro models.
| CAS# | Formula | Molar Mass |
|---|---|---|
| 80714-61-0 | C₃₇H₅₁N₉O₁₀S | 813.9 g/mol |
All products are shipped in lyophilized form and must be reconstituted for in-vitro research applications. Refer to the Certificate of Analysis for purity and identity specifications.
A synthetic heptapeptide derived from a fragment of the natural ACTH hormone.
What is Semax?
Semax was developed in the 1980s at the Institute of Molecular Genetics of the Russian Academy of Sciences by a team led by Nikolai Myasoedov and Isaak Ashmarin. The researchers were investigating fragments of adrenocorticotropic hormone (ACTH) that retained neurotropic activity without the hormonal effects on the adrenal glands.
The ACTH(4-10) fragment studied by the group was rapidly degraded in preclinical models. By adding a Pro-Gly-Pro tripeptide to the C-terminusu2014the same modification later used in Selanku2014they produced a heptapeptide with improved stability characteristics in published assays.
Semax has been the subject of preclinical and clinical investigation in Russia since the early 1990s. Published research has examined its interactions with BDNF and NGF signaling, melanocortin receptors, and monoaminergic pathways. This product is intended for research use only.
What is Semax studied for?
The following research areas represent documented studies available in the scientific literature. We make no claims regarding the benefits, efficacy, or therapeutic applications of this product.
Melanocortin Receptor Research
In preclinical models, Semax has been examined for interactions with MC3R and MC4R melanocortin receptors in central-nervous-system tissue.
ACTH(4-10) Fragment Research
Published in vitro and rodent studies have examined Semax alongside its parent ACTH(4-10) fragment within the nootropic research category.
BDNF & TrkB Expression Research
Laboratory studies have examined Semax's associations with BDNF and TrkB mRNA expression in rat hippocampal tissue.
NGF Signaling Research
Preclinical research has examined Semax's associations with nerve growth factor (NGF) and TrkA receptor expression in rodent CNS models.
Ischemia-Model Research
Published rodent studies have examined Semax in preclinical ischemia and cerebrovascular-insufficiency models.
Monoaminergic Pathway Research
In vitro and in vivo investigations have characterized Semax's associations with dopamine and serotonin metabolism in rat brain tissue.
How should Semax be stored?
All of our products are manufactured using the Lyophilization (Freeze Drying) process, which ensures that our products remain 100% stable for shipping for up to 3-4 months.
Once the peptides are reconstituted (mixed with bacteriostatic water), they must be stored in the fridge to maintain stability.
After reconstitution, the peptides will remain stable for up to 30 days.
Certificate of Analysis
All Semax batches are independently tested by a third-party laboratory for purity and identity verification via HPLC with UV detection coupled with Mass Spectrometry.
HPLC Purity
—
No Certificate of Analysis is available for the selected size yet. Contact support for batch-specific documentation.
COA documents are updated with each new batch. Contact support for batch-specific documentation.
Clinical References
- Ashmarin IP, et al. The nootropic drug Semax: a review of its mechanisms of action. Neuroscience and Behavioral Physiology. 2005.
- Dolotov OV, et al. Semax regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006. PubMed: 16996037
- Gusev EI, et al. Semax in prevention of disease progress in patients with cerebrovascular insufficiency. Zhurnal Nevrologii i Psikhiatrii. 2005.
- Agapova TY, et al. Effects of Semax on dopamine and serotonin metabolism in rat brain. Doklady Biological Sciences. 2007.
